Oppenheimer & Co. Inc. cut its stake in Savara Inc (NASDAQ:SVRA - Free Report) by 86.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,600 shares of the company's stock after selling 100,004 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in Savara were worth $48,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Wellington Management Group LLP grew its holdings in Savara by 22.9% in the third quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company's stock worth $36,566,000 after purchasing an additional 1,608,522 shares during the period. Vestal Point Capital LP raised its stake in Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company's stock valued at $34,302,000 after buying an additional 1,600,000 shares during the last quarter. Jennison Associates LLC raised its stake in Savara by 17.5% during the third quarter. Jennison Associates LLC now owns 6,732,776 shares of the company's stock valued at $28,547,000 after buying an additional 1,001,296 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Savara by 238.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company's stock worth $3,865,000 after acquiring an additional 642,259 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Savara by 15.7% in the third quarter. State Street Corp now owns 4,138,276 shares of the company's stock worth $17,546,000 after acquiring an additional 560,242 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on SVRA shares. JMP Securities reiterated a "market outperform" rating and issued a $9.00 price target on shares of Savara in a research note on Thursday, December 19th. Wells Fargo & Company initiated coverage on shares of Savara in a report on Friday, December 20th. They set an "overweight" rating and a $8.00 price target on the stock. HC Wainwright decreased their price objective on shares of Savara from $10.00 to $6.00 and set a "buy" rating for the company in a report on Wednesday, November 13th. Finally, Evercore ISI reaffirmed an "in-line" rating and issued a $5.00 price objective (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $8.83.
View Our Latest Report on Savara
Insider Transactions at Savara
In related news, CEO Matthew Pauls sold 54,702 shares of the business's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares in the company, valued at approximately $5,085,414.49. The trade was a 3.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 5.13% of the company's stock.
Savara Stock Performance
SVRA stock traded up $0.16 on Thursday, hitting $2.76. The company had a trading volume of 1,083,959 shares, compared to its average volume of 1,241,226. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara Inc has a 12-month low of $2.26 and a 12-month high of $5.34. The stock has a market cap of $472.81 million, a price-to-earnings ratio of -6.41 and a beta of 0.60. The stock's 50-day simple moving average is $2.76 and its 200 day simple moving average is $3.38.
Savara Company Profile
(
Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Read More
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
